欧康维视生物(01477.HK)与Alimera订立独家许可协议
欧康维视生物-B(01477.HK)公布,於4月14日旗下附属香港欧康维视与美国生物制药公司Alimera已订立独家许可协议,据此,Alimera 同意就於经许可地区之许可产品向集团授出许可权。香港欧康维视同意向Alimera支付预付款1,000万美元及於达致独家许可协议所协定的许可产品某一销售净额後支付金额最高为8,900万美元的总潜在销售里程碑付款。
许可产品为190微克氟轻松玻璃体内植入剂(0.19毫克),已获得美国食品药品监督管理局的监管批准,且以商号「ILUVIEN」上市。许可产品通过於眼部连续使用最多36个月的微量非专有皮质类固醇类固醇氟轻松酮(FAc)治疗糖尿病性黄斑水肿(DME)。
经许可地区涉及亚洲多国,包括大中华、韩国、汶莱、柬埔寨、东帝汶、印尼、老挝、马来西亚、缅甸、菲律宾、新加坡、泰国及越南。
同时,公司与Alimera订立股份购买协议,公司计划认购Alimera 114.49万股股份,总代价约为1,000万美元。於股份购买协议项下之交易完成後,公司持有Alimera已发行及发行在外普通股股份总数约16.6%。另公司同意向Alimera发行100万份认股权证。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.